Contact
searchSearch
HMP Global
Login

Diffuse Large B-Cell Lymphoma Specialty Channel

Diffuse Large B-Cell Lymphoma
Specialty Channel
Chan Cheah, MBBS
Conference Coverage
Epcoritamab Plus R-Mini-CHOP Demonstrates Durable Efficacy and Manageable Safety for Elderly Patients With DLBCL: 2-Year Results From EPCORE NHL-2
12/23/2025
Epcoritamab plus R-mini-CHOP achieved high and durable response rates with manageable toxicity among elderly, treatment-naïve patients with DLBCL, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Epcoritamab plus R-mini-CHOP achieved high and durable response rates with manageable toxicity among elderly, treatment-naïve patients with DLBCL, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Epcoritamab plus R-mini-CHOP...
12/23/2025
Oncology
Krish Patel, MD
Conference Coverage
Quality Improvement Project Identifies Knowledge Gaps and Barriers to Bispecific Antibody Use in Community Oncology Practices
12/17/2025
Krish Patel, MD
At the 2025 ASH Annual Meeting & Exposition, Krish Patel, MD, shared insights into the development of a quality improvement initiative aimed to identify barriers of bispecific antibody use in community oncology practices.
At the 2025 ASH Annual Meeting & Exposition, Krish Patel, MD, shared insights into the development of a quality improvement initiative aimed to identify barriers of bispecific antibody use in community oncology practices.
At the 2025 ASH Annual Meeting &...
12/17/2025
Oncology
Conference Coverage
Real-World ctDNA Monitoring Shows MRD Clearance Predicts Relapse Risk and Survival Outcomes for DLBCL: HOVON-902 Analysis
12/11/2025
Emily Estrada
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring...
12/11/2025
Oncology
Conference Coverage
Odronextamab Plus CHOP Demonstrates High Response Rates and Manageable Safety for Previously Untreated DLBCL: First Results From OLYMPIA-3 Trial
12/03/2025
Emily Estrada
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP...
12/03/2025
Oncology
Conference Coverage
Epcoritamab Monotherapy Demonstrates High Response Rates and Durable MRD Negativity in Elderly, Chemotherapy-Ineligible 1L DLBCL Patients: Interim Results from EPCORE DLBCL-3
12/03/2025
Emily Estrada
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous...
12/03/2025
Oncology
Conference Coverage
Zanubrutinib Plus R-CHOP Therapy Shows Promising Efficacy, Acceptable Safety Among Patients With DLBCL Harboring Specific Gene Subtypes
12/02/2025
Emily Estrada
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy...
12/02/2025
Oncology
Conference Coverage
Subcutaneous Mosunetuzumab Shows Efficacy and Safety Among Elderly, Chemotherapy-Ineligible Patients With DLBCL: MorningSun Trial
12/02/2025
Emily Estrada
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at...
12/02/2025
Oncology
Quiz
Polatuzumab-Based Therapy for R/R DLBCL
12/01/2025
True or False: Polatuzumab vedotin combined with rituximab and bendamustine demonstrated inferior overall survival compared with conventional chemotherapy among patients with R/R diffuse large B-cell lymphoma.
True or False: Polatuzumab vedotin combined with rituximab and bendamustine demonstrated inferior overall survival compared with conventional chemotherapy among patients with R/R diffuse large B-cell lymphoma.
True or False: Polatuzumab...
12/01/2025
Oncology
News
Nivolumab Plus R-CHOP Shows Promising Efficacy and Tolerability for Newly Diagnosed DLBCL
12/01/2025
Emily Estrada
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a...
12/01/2025
Oncology
News
Rituximab and Lenalidomide Plus Ibrutinib Therapy Shows Promising Activity, Manageable Toxicity in Real-World Setting for Relapsed/Refractory DLBCL
12/01/2025
Emily Estrada
The combination of rituximab, lenalidomide, and ibrutinib demonstrated promising efficacy and survival outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma in a retrospective real-world analysis.
The combination of rituximab, lenalidomide, and ibrutinib demonstrated promising efficacy and survival outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma in a retrospective real-world analysis.
The combination of rituximab,...
12/01/2025
Oncology
News
Ibrutinib-Based Triple Therapy Yields Durable Responses for Newly Diagnosed Primary CNS DLBCL
10/28/2025
Emily Estrada
For patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma, first-line treatment with ibrutinib, rituximab, and high-dose methotrexate demonstrated promising outcomes and manageable safety.
For patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma, first-line treatment with ibrutinib, rituximab, and high-dose methotrexate demonstrated promising outcomes and manageable safety.
For patients with newly...
10/28/2025
Oncology

News

Conference Coverage
Real-World ctDNA Monitoring Shows MRD Clearance Predicts Relapse Risk and Survival Outcomes for DLBCL: HOVON-902 Analysis
12/11/2025
Emily Estrada
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring...
12/11/2025
Oncology
Conference Coverage
Odronextamab Plus CHOP Demonstrates High Response Rates and Manageable Safety for Previously Untreated DLBCL: First Results From OLYMPIA-3 Trial
12/03/2025
Emily Estrada
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP...
12/03/2025
Oncology
Conference Coverage
Epcoritamab Monotherapy Demonstrates High Response Rates and Durable MRD Negativity in Elderly, Chemotherapy-Ineligible 1L DLBCL Patients: Interim Results from EPCORE DLBCL-3
12/03/2025
Emily Estrada
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous...
12/03/2025
Oncology
Conference Coverage
Zanubrutinib Plus R-CHOP Therapy Shows Promising Efficacy, Acceptable Safety Among Patients With DLBCL Harboring Specific Gene Subtypes
12/02/2025
Emily Estrada
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy...
12/02/2025
Oncology
Conference Coverage
Subcutaneous Mosunetuzumab Shows Efficacy and Safety Among Elderly, Chemotherapy-Ineligible Patients With DLBCL: MorningSun Trial
12/02/2025
Emily Estrada
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at...
12/02/2025
Oncology
News
Nivolumab Plus R-CHOP Shows Promising Efficacy and Tolerability for Newly Diagnosed DLBCL
12/01/2025
Emily Estrada
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a...
12/01/2025
Oncology
News
Rituximab and Lenalidomide Plus Ibrutinib Therapy Shows Promising Activity, Manageable Toxicity in Real-World Setting for Relapsed/Refractory DLBCL
12/01/2025
Emily Estrada
The combination of rituximab, lenalidomide, and ibrutinib demonstrated promising efficacy and survival outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma in a retrospective real-world analysis.
The combination of rituximab, lenalidomide, and ibrutinib demonstrated promising efficacy and survival outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma in a retrospective real-world analysis.
The combination of rituximab,...
12/01/2025
Oncology
News
Ibrutinib-Based Triple Therapy Yields Durable Responses for Newly Diagnosed Primary CNS DLBCL
10/28/2025
Emily Estrada
For patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma, first-line treatment with ibrutinib, rituximab, and high-dose methotrexate demonstrated promising outcomes and manageable safety.
For patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma, first-line treatment with ibrutinib, rituximab, and high-dose methotrexate demonstrated promising outcomes and manageable safety.
For patients with newly...
10/28/2025
Oncology
News
Polatuzumab-Based Therapy Improves Survival for Patients With R/R DLBCL Ineligible for Transplant
10/28/2025
Emily Estrada
Compared with conventional chemotherapy, polatuzumab vedotin combined with rituximab and bendamustine demonstrated superior overall survival among patients with relapsed/refractory diffuse large B-cell lymphoma ineligible for transplant.
Compared with conventional chemotherapy, polatuzumab vedotin combined with rituximab and bendamustine demonstrated superior overall survival among patients with relapsed/refractory diffuse large B-cell lymphoma ineligible for transplant.
Compared with conventional...
10/28/2025
Oncology
News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
Berzosertib Plus Topotecan for Patients With Relapsed Platinum-Resistant Small-Cell Lung Cancer: DDRiver SCLC 250 Study
01/15/2026
Gina Tomaine
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did...
01/15/2026
Oncology
News
Prophylactic Tocilizumab May Limit Tarlatamab Toxicities for High-Risk Patients With Extensive-Stage Small Cell and Neuroendocrine Lung Cancer
01/15/2026
Gina Tomaine
Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a...
Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a...
Tarlatamab for patients with...
01/15/2026
Oncology
News
Oral Iberdomide Combination Demonstrates Clinically Meaningful Activity for R/R Multiple Myeloma
01/14/2026
Emily Estrada
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of...
01/14/2026
Oncology
News
High Non-Relapse Mortality Remains Barrier to Allogeneic Transplantation Success Rates for Patients With Myelofibrosis
01/14/2026
Emily Estrada
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with...
01/14/2026
Oncology
News
Pacritinib Therapy Shows Improved Symptom Reduction and Spleen Response for Patients With Myelofibrosis and Thrombocytopenia
01/14/2026
Emily Estrada
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed...
01/14/2026
Oncology
News
Pegylated Liposomal Doxorubicin Significantly Extends Progression-Free Survival in Advanced Desmoid Tumors
01/13/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged PFS compared with placebo treatment among patients with advanced or refractory desmoid tumors.
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged PFS compared with placebo treatment among patients with advanced or refractory desmoid tumors.
Results from a phase 3 trial...
01/13/2026
Oncology
News
Andamertinib Demonstrates Clinical Promise for Pretreated Patients With EGFR-Mutated NSCLC
01/13/2026
Stephanie Holland
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON...
01/13/2026
Oncology
Conference Coverage
Lirafugratinib Demonstrates Efficacy, Safety for Previously Treated Patients With FGFR2 Fusion-Positive Cholangiocarcinoma
01/13/2026
Stephanie Holland
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2...
01/13/2026
Oncology
News
Eflornithine Plus Lomustine vs Lomustine Monotherapy for Recurrent Grade 3 Astrocytoma: Phase 3 STELLAR Trial
01/13/2026
Gina Tomaine
Results showed that eflornithine combined with lomustine significantly prolonged both progression-free and overall survival for patients with recurrent IDH-mutant, grade 3 astrocytoma, compared with lomustine monotherapy.
Results showed that eflornithine combined with lomustine significantly prolonged both progression-free and overall survival for patients with recurrent IDH-mutant, grade 3 astrocytoma, compared with lomustine monotherapy.
Results showed that eflornithine...
01/13/2026
Oncology
Conference Coverage
Addition of Tislelizumab to Neoadjuvant Chemoradiotherapy Shows Clinical Promise for Gastric/GEJ Cancer
01/13/2026
Stephanie Holland
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the...
01/13/2026
Oncology

Interactive Features

Quiz
Polatuzumab-Based Therapy for R/R DLBCL
12/01/2025
True or False: Polatuzumab vedotin combined with rituximab and bendamustine demonstrated inferior overall survival compared with conventional chemotherapy among patients with R/R diffuse large B-cell lymphoma.
True or False: Polatuzumab vedotin combined with rituximab and bendamustine demonstrated inferior overall survival compared with conventional chemotherapy among patients with R/R diffuse large B-cell lymphoma.
True or False: Polatuzumab...
12/01/2025
Oncology
Quiz
Polatuzumab-Based Regimens for R/R DLBCL
10/28/2025
True or False: Compared to patients with R/R DLBCL treated with traditional salvage therapies, patients treated with polatuzumab vedotin and zanubrutinib combined with either rituximab or obinutuzumab demonstrated inferior clinical outcomes...
True or False: Compared to patients with R/R DLBCL treated with traditional salvage therapies, patients treated with polatuzumab vedotin and zanubrutinib combined with either rituximab or obinutuzumab demonstrated inferior clinical outcomes...
True or False: Compared to...
10/28/2025
Oncology
Quiz
Epcoritamab Plus R-ICE for R/R DLBCL
09/26/2025
True or False: According to results from the EPCORE NHL-2 clinical trial, the addition of epcoritamab to standard R-ICE therapy demonstrated high overall and complete response rates among patients with R/R DLBCL eligible for autologous stem...
True or False: According to results from the EPCORE NHL-2 clinical trial, the addition of epcoritamab to standard R-ICE therapy demonstrated high overall and complete response rates among patients with R/R DLBCL eligible for autologous stem...
True or False: According to...
09/26/2025
Oncology
Quiz
Efficacy and Safety of Tazemetostat for R/R DLBCL and FL
08/25/2025
True or False: Based on results from a meta-analysis evaluating the safety and efficacy of tazemetostat among patients with R/R FL or DLBCL, the EZH2 inhibitor demonstrated promise as a viable treatment option, demonstrating meaningful...
True or False: Based on results from a meta-analysis evaluating the safety and efficacy of tazemetostat among patients with R/R FL or DLBCL, the EZH2 inhibitor demonstrated promise as a viable treatment option, demonstrating meaningful...
True or False: Based on results...
08/25/2025
Oncology
Quiz
Autologous Hematopoietic Cell Transplantation or CAR-T Therapy for Patients With Relapsed LBCL
09/30/2024
True or False: According to results from a retrospective observational study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation fails to...
True or False: According to results from a retrospective observational study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation fails to...
True or False: According to...
09/30/2024
Oncology
Quiz
Induction Therapy With High-Dose Chemo, Autologous HSCT in Patients With PCNSL
04/11/2024
04/11/2024
Oncology
Quiz
Blinatumomab After ASCT as a Treatment Option Among Patients With Relapsed DLBCL
02/27/2024
02/27/2024
Oncology
Quiz
Treating DLBCL With Tafasitamab Plus R-CHOP, With or Without Lenalidomide
12/15/2023
True or False: According to findings from the phase 1b First-MIND study, tafasitamab plus the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen with or without the addition of lenalidomide demonstrated...
True or False: According to findings from the phase 1b First-MIND study, tafasitamab plus the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen with or without the addition of lenalidomide demonstrated...
True or False: According to...
12/15/2023
Oncology
Quiz
Acalabrutinib Plus Danvatirsen for R/R DLBCL
12/05/2023
What were the key findings of the phase 1 PRISM trial, which investigated the use of BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen among patients with R/R DLBCL?
What were the key findings of the phase 1 PRISM trial, which investigated the use of BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen among patients with R/R DLBCL?
What were the key findings of...
12/05/2023
Oncology
Quiz
Standard vs 4-Cycle Regimen of R-CHOP for Non-Bulky, Low-Risk DLBCL
11/07/2023
According to findings from a phase 3 trial, how did a 4-cycle regimen of R-CHOP compare to the standard regimen in treating patients with non-bulky, low-risk DLBCL?
According to findings from a phase 3 trial, how did a 4-cycle regimen of R-CHOP compare to the standard regimen in treating patients with non-bulky, low-risk DLBCL?
According to findings from a...
11/07/2023
Oncology
Quiz
Rovadicitinib for Ruxolitinib-Resistant or Intolerant Myelofibrosis
01/14/2026
True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...
True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...
True or False: The...
01/14/2026
Oncology
Quiz
CMS4 and Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/13/2026
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus...
01/13/2026
Oncology
Quiz
Eflornithine Plus Lomustine for Recurrent Grade 3 Astrocytoma
01/13/2026
True or false: Eflornithine combined with lomustine significantly prolonged both progression-free and overall survival in patients with recurrent IDH-mutant, grade 3 astrocytoma following prior radiotherapy and temozolomide, compared with...
True or false: Eflornithine combined with lomustine significantly prolonged both progression-free and overall survival in patients with recurrent IDH-mutant, grade 3 astrocytoma following prior radiotherapy and temozolomide, compared with...
True or false: Eflornithine...
01/13/2026
Oncology
Quiz
Chidamide Plus Azacitidine Maintenance Therapy for AML
01/12/2026
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following...
01/12/2026
Oncology
Quiz
Treatment of Recurrent Refractory Pediatric Low-Grade Glioma (pLGG): Pre-Content Quiz
01/02/2026
01/02/2026
Oncology
Quiz
Molecular Drivers of Pigmented Villonodular Synovitis
12/18/2025
Which of the following molecular features were found to be most strongly associated with disease progression in pigmented villonodular synovitis?
Which of the following molecular features were found to be most strongly associated with disease progression in pigmented villonodular synovitis?
Which of the following molecular...
12/18/2025
Oncology
Quiz
Evaluating Pembrolizumab Plus Chemotherapy in Extensive SCLC
12/17/2025
The phase 2 REACTION trial aimed to assess the addition of pembrolizumab to first-line platinum-etoposide in chemo-sensitive patients with extensive-stage small cell lung cancer. Which of the following best summarizes the efficacy findings?
The phase 2 REACTION trial aimed to assess the addition of pembrolizumab to first-line platinum-etoposide in chemo-sensitive patients with extensive-stage small cell lung cancer. Which of the following best summarizes the efficacy findings?
The phase 2 REACTION trial aimed...
12/17/2025
Oncology
Quiz
Early Switch to Camizestrant at ESR1 Mutation Emergence in HR-Positive, HER2-Negative Advanced Breast Cancer
12/12/2025
The phase 3 SERENA-6 trial evaluated an early switch to camizestrant plus continued CDK4/6 inhibition at the time of ESR1 mutation emergence in patients with HR-positive, HER2-negative advanced breast cancer.Which of the following best...
The phase 3 SERENA-6 trial evaluated an early switch to camizestrant plus continued CDK4/6 inhibition at the time of ESR1 mutation emergence in patients with HR-positive, HER2-negative advanced breast cancer.Which of the following best...
The phase 3 SERENA-6 trial...
12/12/2025
Oncology
Quiz
Niraparib Plus Dostarlimab for Patients With Germline BRCA1/2-Mutated TNBC
12/11/2025
According to the phase 2 TBCRC 056 trial of neoadjuvant niraparib plus dostarlimab in patients with germline BRCA1/2-mutated triple-negative breast cancer, which of the following best describes the observed antitumor and immunologic activity?
According to the phase 2 TBCRC 056 trial of neoadjuvant niraparib plus dostarlimab in patients with germline BRCA1/2-mutated triple-negative breast cancer, which of the following best describes the observed antitumor and immunologic activity?
According to the phase 2 TBCRC...
12/11/2025
Oncology
Quiz
FDA Approves Tarlatamab for Extensive-Stage Small Cell Lung Cancer
12/10/2025
Which of the following statements best reflects the efficacy outcomes that supported conversion of tarlatamab’s accelerated approval to traditional approval for previously treated ES-SCLC in the phase 3 DeLLphi-304 trial?
Which of the following statements best reflects the efficacy outcomes that supported conversion of tarlatamab’s accelerated approval to traditional approval for previously treated ES-SCLC in the phase 3 DeLLphi-304 trial?
Which of the following...
12/10/2025
Oncology

Recent News

Conference Coverage
Real-World ctDNA Monitoring Shows MRD Clearance Predicts Relapse Risk and Survival Outcomes for DLBCL: HOVON-902 Analysis
12/11/2025
Emily Estrada
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring...
12/11/2025
Oncology
Conference Coverage
Odronextamab Plus CHOP Demonstrates High Response Rates and Manageable Safety for Previously Untreated DLBCL: First Results From OLYMPIA-3 Trial
12/03/2025
Emily Estrada
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP...
12/03/2025
Oncology
Conference Coverage
Epcoritamab Monotherapy Demonstrates High Response Rates and Durable MRD Negativity in Elderly, Chemotherapy-Ineligible 1L DLBCL Patients: Interim Results from EPCORE DLBCL-3
12/03/2025
Emily Estrada
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous...
12/03/2025
Oncology
Conference Coverage
Zanubrutinib Plus R-CHOP Therapy Shows Promising Efficacy, Acceptable Safety Among Patients With DLBCL Harboring Specific Gene Subtypes
12/02/2025
Emily Estrada
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy...
12/02/2025
Oncology
Conference Coverage
Subcutaneous Mosunetuzumab Shows Efficacy and Safety Among Elderly, Chemotherapy-Ineligible Patients With DLBCL: MorningSun Trial
12/02/2025
Emily Estrada
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at...
12/02/2025
Oncology
News
Nivolumab Plus R-CHOP Shows Promising Efficacy and Tolerability for Newly Diagnosed DLBCL
12/01/2025
Emily Estrada
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a...
12/01/2025
Oncology
News
Rituximab and Lenalidomide Plus Ibrutinib Therapy Shows Promising Activity, Manageable Toxicity in Real-World Setting for Relapsed/Refractory DLBCL
12/01/2025
Emily Estrada
The combination of rituximab, lenalidomide, and ibrutinib demonstrated promising efficacy and survival outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma in a retrospective real-world analysis.
The combination of rituximab, lenalidomide, and ibrutinib demonstrated promising efficacy and survival outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma in a retrospective real-world analysis.
The combination of rituximab,...
12/01/2025
Oncology
News
Ibrutinib-Based Triple Therapy Yields Durable Responses for Newly Diagnosed Primary CNS DLBCL
10/28/2025
Emily Estrada
For patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma, first-line treatment with ibrutinib, rituximab, and high-dose methotrexate demonstrated promising outcomes and manageable safety.
For patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma, first-line treatment with ibrutinib, rituximab, and high-dose methotrexate demonstrated promising outcomes and manageable safety.
For patients with newly...
10/28/2025
Oncology
News
Polatuzumab-Based Therapy Improves Survival for Patients With R/R DLBCL Ineligible for Transplant
10/28/2025
Emily Estrada
Compared with conventional chemotherapy, polatuzumab vedotin combined with rituximab and bendamustine demonstrated superior overall survival among patients with relapsed/refractory diffuse large B-cell lymphoma ineligible for transplant.
Compared with conventional chemotherapy, polatuzumab vedotin combined with rituximab and bendamustine demonstrated superior overall survival among patients with relapsed/refractory diffuse large B-cell lymphoma ineligible for transplant.
Compared with conventional...
10/28/2025
Oncology
News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
Berzosertib Plus Topotecan for Patients With Relapsed Platinum-Resistant Small-Cell Lung Cancer: DDRiver SCLC 250 Study
01/15/2026
Gina Tomaine
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did...
01/15/2026
Oncology
News
Prophylactic Tocilizumab May Limit Tarlatamab Toxicities for High-Risk Patients With Extensive-Stage Small Cell and Neuroendocrine Lung Cancer
01/15/2026
Gina Tomaine
Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a...
Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a...
Tarlatamab for patients with...
01/15/2026
Oncology
News
Oral Iberdomide Combination Demonstrates Clinically Meaningful Activity for R/R Multiple Myeloma
01/14/2026
Emily Estrada
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of...
01/14/2026
Oncology
News
High Non-Relapse Mortality Remains Barrier to Allogeneic Transplantation Success Rates for Patients With Myelofibrosis
01/14/2026
Emily Estrada
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with...
01/14/2026
Oncology
News
Pacritinib Therapy Shows Improved Symptom Reduction and Spleen Response for Patients With Myelofibrosis and Thrombocytopenia
01/14/2026
Emily Estrada
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed...
01/14/2026
Oncology
News
Pegylated Liposomal Doxorubicin Significantly Extends Progression-Free Survival in Advanced Desmoid Tumors
01/13/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged PFS compared with placebo treatment among patients with advanced or refractory desmoid tumors.
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged PFS compared with placebo treatment among patients with advanced or refractory desmoid tumors.
Results from a phase 3 trial...
01/13/2026
Oncology
News
Andamertinib Demonstrates Clinical Promise for Pretreated Patients With EGFR-Mutated NSCLC
01/13/2026
Stephanie Holland
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON...
01/13/2026
Oncology
Conference Coverage
Lirafugratinib Demonstrates Efficacy, Safety for Previously Treated Patients With FGFR2 Fusion-Positive Cholangiocarcinoma
01/13/2026
Stephanie Holland
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2...
01/13/2026
Oncology
News
Eflornithine Plus Lomustine vs Lomustine Monotherapy for Recurrent Grade 3 Astrocytoma: Phase 3 STELLAR Trial
01/13/2026
Gina Tomaine
Results showed that eflornithine combined with lomustine significantly prolonged both progression-free and overall survival for patients with recurrent IDH-mutant, grade 3 astrocytoma, compared with lomustine monotherapy.
Results showed that eflornithine combined with lomustine significantly prolonged both progression-free and overall survival for patients with recurrent IDH-mutant, grade 3 astrocytoma, compared with lomustine monotherapy.
Results showed that eflornithine...
01/13/2026
Oncology
Conference Coverage
Addition of Tislelizumab to Neoadjuvant Chemoradiotherapy Shows Clinical Promise for Gastric/GEJ Cancer
01/13/2026
Stephanie Holland
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the...
01/13/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use